Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced new data showing that the deep learning capabilities of the Nucleai platform accurately analyzed and classified the spatial arrangement of immune cells in the tumor microenvironment (TME) to identify metastatic non-small cell lung cancer (mNSCLC) patients who are likely to benefit from pembrolizumab, an immune checkpoint inhibitor (ICI) therapy. This work is part of several ongoing studies examining the spatial arrangement of immune cells in the TME and the significance of this research is its potential to identify new predictive spatial immune signatures in a large-scale, multi-site patient dataset.

Contact us

To request more information or to get a demo, quote for our products, please fill out the form below.

Unsubscribe at any time using the link in our emails.
For details, see our Privacy Policy.

Add Your Heading Text Here